Novartis AG (NVS) presented new subgroup analyses from its pivotal PSMAddition Phase 3 trial, showing that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC) consistently improved outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC).